Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results
– Patient enrollment continues in KOMET-001 Phase 1b study of ziftomenib (KO-539) in AML –…
– Patient enrollment continues in KOMET-001 Phase 1b study of ziftomenib (KO-539) in AML –…
Safety-critical multicore 6U solutions accelerate data-intensive sensor processing applications while lowering risk Mercury’s new BuiltSAFE…
BENSALEM, Pa.–(BUSINESS WIRE)–Law Offices of Howard G. Smith announces an investigation on behalf of C3.ai,…
BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–CANbridge Pharmaceuticals, Inc. (“CANbridge”, stock code 1228.HK), a leading China-based global…
NEW YORK–(BUSINESS WIRE)–#KBRA–KBRA releases a report analyzing the 1-year and lifetime transition of its ratings…
LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm,…
LADERA RANCH, CALIF.–(BUSINESS WIRE)–SmartStop Self Storage REIT, Inc. (“SmartStop” or the “Company”), a self-managed and…
LOS ANGELES–(BUSINESS WIRE)–The Law Offices of Frank R. Cruz announces an investigation of C3.ai, Inc….
NEW YORK & DUBLIN–(BUSINESS WIRE)–#KBRA–KBRA and KBRA Europe (collectively, KBRA) releases a brief report highlighting…
SAN DIEGO–(BUSINESS WIRE)–#Appointment–Taoglas®, a leading provider of advanced technology for a smarter world, today announced…
HOUSTON–(BUSINESS WIRE)–Oceaneering International, Inc. (“Oceaneering”) (NYSE:OII) today reported a net loss of $38.8 million, or…
COVINGTON, La.–(BUSINESS WIRE)–Globalstar, Inc. (NYSE American: GSAT) today announced operating and financial results for the…
Key 2021 and post period events: Appointment of Dr. Paul Stoffels1 as new CEO, effective…
– BDSI Acquisition Expected to Close Late Q1 2022 – – 2022 Revenue Guidance of…
Phase 2a study in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) enrollment closed; topline…
Four top-line data readouts expected in 2022 from ongoing oral AMT-101 Phase 2 trials, as…
Initiating Phase 1 dose escalation study of MGC018 in combination with lorigerlimab (formerly MGD019) in…
FDA Approved TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of…
NDA submission of sparsentan in IgA nephropathy on-track for first quarter 2022 Company positioned for…
Announced completion of pre-BLA meeting with the FDA for omburtamab BLA resubmission expected by the…